-
Markets Reverse Early Morning Losses; Still Lower On The Day
Thursday, August 28, 2014 - 4:40pm | 2611Read More...U.S. stocks declined as geopolitical concerns outweighed an improved economic read on second-quarter growth. Ukraine's President stated that Russian troops had crossed in to Ukraine territory and were fighting alongside Russian supported separatists. Markets initially traded lower on the...
-
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
Tuesday, August 26, 2014 - 4:42pm | 2835Read More...U.S. stocks rose, lifting the Dow to new historical all-time highs of 17,153.80 following a better than expected rise in orders of durable goods. Consumer confidence improved in August, helping market sentiments while investors and traders placed less emphasis on a report that home prices are...
-
S&P 500 Hits 2,000 Milestone As Bullish Momentum Continues
Monday, August 25, 2014 - 4:49pm | 2139Read More...U.S. stocks were higher on Monday as the S&P 500 traded above the 2,000 mark for the first time ever, creating a new historical intra-day high of 2001.94. The S&P 500's milestone came on a relatively quiet day for stocks. A light news-load isn't necessarily a bad thing for the...
-
Stifel Downgrades InterMune; Roche Offer 'Appropriate Ending'
Monday, August 25, 2014 - 11:34am | 329Read More...Shares of InterMune (NASDAQ: ITMN) were downgraded to Hold from Buy by Stifel following Roche's proposed $8.3 billion acquisition over the weekend. InterMune has been the subject of various takeover rumors. On August 13, Bloomberg reported that Roche, along with other European drug markers...
-
InterMune Leads The Pack
Wednesday, July 30, 2014 - 10:55am | 379Read More...Warning signs are popping up all over the place in the stock market. The Dow has just formed a bearish pattern and confirmed that pattern. In addition, the Dow never did confirm last week’s high in the S&P 500. Momentum has been on the decline in most major indices. The common...
-
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
Thursday, July 3, 2014 - 10:36am | 873Read More...Cowen analysts recently released a research report that focused on biotech stocks with promising Phase 3 data leading into the U.S. Food and Drug Administration (FDA) approval process. ACADIA Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), InterMune (NASDAQ: ITMN) and...
-
Market Wrap For February 25: Markets End The Day Relatively Flat
Tuesday, February 25, 2014 - 5:38pm | 2952Read More...U.S. stocks fell on Tuesday as investors found a decline in consumer confidence as reason enough to keep stocks from moving higher. The S&P 500 retreated from its record all time high set yesterday but took a run above the 1,850 level in the late morning. The all time high for the index is...
-
Market Wrap For January 10: Job Growth Weak, But Unemployment Falls
Friday, January 10, 2014 - 5:53pm | 2337Read More...Major indices ended the day little changed as investors and traders were not sure how to react to today's job reports. 74,000 jobs were added, well below the estimated 196,000. The report proved to be a complete contradiction to every other report previously seen. Related: ETFs Moving On The...
-
UPDATE: Brean Murray Color on InterMune Initiation
Wednesday, July 13, 2011 - 7:39am | 99Read More...Brean Murray, Carret & Co., which initiated InterMune Inc. (NASDAQ: ITMN) at Buy, is providing some color on the stock. “We are initiating coverage of InterMune with a Buy rating and a $50 price target,” Brean Murray writes. “InterMune is beginning to launch Esbriet, a newly approved drug for...
-
JP Morgan Upgrades InterMune To Overweight, Raises PT To $45
Friday, June 17, 2011 - 6:12am | 27Read More...JP Morgan has upgraded InterMune (NASDAQ: ITMN) from Neutral to Overweight and has raised the price target from $38 to $45.
-
JP Morgan Raises PT On InterMune To $38
Thursday, February 17, 2011 - 9:04am | 26Read More...JP Morgan has raised the price target on InterMune (NASDAQ: ITMN) from $32 to $38 and maintains its Neutral rating.
-
Wells Fargo Resumes Coverage On InterMune With $13-15 Valuation Range
Friday, December 10, 2010 - 11:33am | 77Read More...Wells Fargo is resuming coverage on InterMune, Inc.'s (NASDAQ: ITMN) with a change in analyst, a Market Perform rating, and a $13-$15 valuation range. “ITMN's lead drug, pirfenidone, produced mixed phase III results in idiopathic pulmonary fibrosis (IPF), with one study reaching its primary...
-
InterMune Halted Pending News
Tuesday, May 4, 2010 - 1:57pm | 93Read More...Shares of InterMune (NASDAQ: ITMN) were halted a short while ago pending news. More than likely it is related to their drug Esbriet(R) (pirfenidone), which is used to combat pulmonary fibrosis. Prior to the halting, the shares were down $5.41% to $45.44. Their were a few options trades today in the...
-
Thomas Weisel Partners More Than Double InterMune (ITMN) Price Target To $55
Wednesday, March 10, 2010 - 9:15am | 202Read More...Thomas Weisel Partners analyst Stephen Willey maintained his Overweight rating for shares of InterMune, Inc. (Nasdaq: ITMN) and raised the price target from $26 to $55. The day before, a panel at the Food and Drug Administration recommended InterMune's pirfenidone for the treatment of idiopathic...
-
InterMune (ITMN) Shares Jump 63% After FDA Announcement
Tuesday, March 9, 2010 - 6:56pm | 84Read More...Shares of InterMune, Inc. (Nasdaq: ITMN) surged more than 60% after a panel at the Food and Drug Administration recommended the company's Esbriet for treatment of idiopathic pulmonary fibrosis. IPF is a rare and deadly lung disease with no existing FDA approved treatments, which affects nearly 200,...
